URGN
NASDAQUroGen Pharma Ltd.
Price$24.12-0.20 (-0.84%)
01:30 PM07:45 PM
News · 26 weeks40+50%
2025-11-022026-04-26
Mix2390d
- Other9(39%)
- Insider6(26%)
- SEC Filings5(22%)
- Earnings2(9%)
- Analyst1(4%)
Latest news
25 items- SECSEC Form PRE 14A filed by UroGen Pharma Ltd.PRE 14A - UroGen Pharma Ltd. (0001668243) (Filer)
- ANALYSTJefferies initiated coverage on UroGen Pharma with a new price targetJefferies initiated coverage of UroGen Pharma with a rating of Buy and set a new price target of $40.00
- PRUroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial CancerPRINCETON, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the launch of its "LG-UTUC Luminaries" initiative, recognizing clinicians and institutions demonstrating leadership, expertise, and a commitment to advancing low‑grade upper tract urothelial cancer (LG‑UTUC) care. LG‑UTUC is a rare form of cancer affecting an estimated 6,000-7,000 patients each year in the U.S., which represents approximately 40% of patients diagnosed in the U.S. annually with UTUC. While typically noninvasive, it often recurs and may require rep
- PRJournal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI72.2% Probability of Remaining Event-Free at 24 Months by Kaplan-Meier Analysis After Achieving Complete Response at Three Months (79.6%) PRINCETON, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the publication of results from the pivotal Phase 3 ENVISION trial of ZUSDURI™ (mitomycin) for intravesical solution in The Journal of Urology. ZUSDURI is indicated for the treatment of adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The publication reports a 72.2% probability
- PRUroGen Applauds BCAN's New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of RecurrenceNational survey of more than 1,100 bladder cancer patients finds nearly 80% report fear of recurrence, rising above 90% among patients under 50Many respondents report undergoing five or more cystoscopies, with some experiencing more than 15 procedures PRINCETON, N.J., March 13, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd., a biotechnology company dedicated to developing innovative therapies for urothelial and specialty cancers, today commended the Bladder Cancer Advocacy Network (BCAN) on its release of The New Faces of Bladder Cancer Report, a national patient-reported survey underscoring the chronic and recurrent nature of bladder cancer. The survey, which captures the experiences of mo
- PRUroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PRINCETON, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units ("RSUs") to 11 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercialization of JELMYTO® (mitomycin) for pyelocalyceal solution and ZUSDUR™ (mitomycin) for intravesical solution, UroGen's only approved products, and the continued development of UroGen's pipeline. Up to 51,200 ordinary shares of UroGen are issuable upon the vesting and settlement of t
- SECSEC Form 10-K filed by UroGen Pharma Ltd.10-K - UroGen Pharma Ltd. (0001668243) (Filer)
- SECUroGen Pharma Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - UroGen Pharma Ltd. (0001668243) (Filer)
- SECUroGen Pharma Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation8-K - UroGen Pharma Ltd. (0001668243) (Filer)
- PRUroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial ResultsCommercial launch is on-track for ZUSDURI™, the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC); net sales in 2025 were $15.8 million, reflecting the initial launch period ahead of the permanent J CodePermanent J Code for ZUSDURI became effective on January 1, 2026, streamlining reimbursement procedures and supporting broader patient accessJELMYTO® achieved net product sales of $94 million in 2025, representing year-over-year underlying demand sales growth of 7%Announced refinancing of existing term loan with Pharmakon Advisors that provides additional non-dilutive capital at more favorable termsCon
- PRUroGen Announces Refinanced Term Loan Agreement with Pharmakon AdvisorsOpportunistic refinancing meaningfully reduces cost of capital with 8.25% fixed interest rate and extends amortization period to Q1 2030 $200 million funded at closing to refinance the existing $125 million debt facility and provide additional non-dilutive capital Additional $50 million tranche available at Company's discretion until June 30, 2027 PRINCETON, N.J., March 02, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, announced it has entered into an agreement with funds managed by Pharmakon Advisors, LP (Pharmakon) to revise the terms of its loan agre
- INSIDERDirector Robinson James A. Jr. converted options into 2,000 units of ordinary shares, increasing direct ownership by 100% to 4,000 units (SEC Form 4)4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- PRZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC• EORTC Recurrence Score Analysis from the Pivotal ENVISION Trial to be Presented at the 2026 American Society of Clinical Oncology's Genitourinary Cancers Symposium (ASCO-GU 2026) PRINCETON, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative, non-surgical therapies for urothelial and specialty cancers, today announced new post-hoc analyses from the Phase 3 ENVISION trial showing that ZUSDURI™ (mitomycin) for intravesical solution (formerly known as UGN-102) achieved durable complete response (CR) rates across European Organization for Research and Treatment of Cancer (EORTC) recurrence score g
- PRUroGen Pharma to Present at the TD Cowen 46th Annual Health Care ConferencePRINCETON, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that management will present at the TD Cowen 46th Annual Health Care Conference to take place March 2-4, 2026. TD Cowen 46th Annual Health Care Conference Date / Time:March 3, 2026, at 1:50 PM ETFormat:Presentation and 1x1 investor meetingsLocation:Boston, MAWebcast Link:here The webcast from the conference will also be available on UroGen's corporate website, under Events & Presentations. A replay will be available for approximately 30 days. About UroGen Pharma
- PRUroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026PRINCETON, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report fourth quarter and full-year 2025 financial results on Monday, March 2nd , 2026, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time. A live public webcast of the earnings conference call can be accessed on UroGen's Investor Relations website. Following the live webcast, a replay will be available on the site for approximately 30 days. About UroGen Pharma
- INSIDERSEC Form 4 filed by Chief Executive Officer Barrett Elizabeth A.4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by UroGen Pharma Ltd.SCHEDULE 13G/A - UroGen Pharma Ltd. (0001668243) (Subject)
- INSIDERGeneral Counsel Smith Jason Drew converted options into 15,500 units of Ordinary Shares and sold $147,262 worth of Ordinary Shares (7,479 units at $19.69), increasing direct ownership by 11% to 55,588 units (SEC Form 4)4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- INSIDERChief Medical Officer Schoenberg Mark sold $145,174 worth of Ordinary Shares (7,373 units at $19.69), decreasing direct ownership by 5% to 144,985 units (SEC Form 4)4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- PRUroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech SummitPRINCETON, N.J., Feb. 04, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that management will present at the Guggenheim Securities Emerging Outlook: Biotech Summit to take place on February 11-12, 2026. Guggenheim Emerging Outlook: Biotech Summit 2026 Date / Time:February 12, 2026, at 2:30 PM ETFormat:Fireside Chat and 1x1 investor meetingsLocation:New York, NYWebcast Link:here The webcast from the conference will also be available on UroGen's corporate website, under Events & Presentations. A replay will be available for approximate
- INSIDERChief Medical Officer Schoenberg Mark converted options into 13,333 units of Ordinary Shares (SEC Form 4)4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Degnan Chris4 - UroGen Pharma Ltd. (0001668243) (Issuer)
- SECSEC Form 144 filed by UroGen Pharma Ltd.144 - UroGen Pharma Ltd. (0001668243) (Subject)
- PRPermanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer TherapyPRINCETON, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that adult patients living with recurrent low-grade intermediate-risk non–muscle invasive bladder cancer (LG-IR-NMIBC) now have improved access to an important therapy, as the permanent Healthcare Common Procedure Coding System Level II J Code for ZUSDURI™ (mitomycin) for intravesical solution became effective on January 1, 2026. The new code, J9282, assigned by the Centers for Medicare & Medicaid Services, is expected to streamline billing and reimbursement proces
- PRUroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PRINCETON, N.J., Dec. 05, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units ("RSUs") to 14 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercialization of Jelmyto® (mitomycin) for pyelocalyceal solution and ZUSDURI™ (mitomycin) for intravesical solution, UroGen's only approved products, and the continued development of UroGen's pipeline. Up to 32,500 ordinary shares of UroGen are issuable upon the vesting and settlement of t